Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Necitumumab Neoadjuvant Study in Squamous Lung Cancer
NCT03574818Phase 2Terminated
- Sponsor
- Montefiore Medical Center
- Start
- May 2018
- Primary completion
- Oct 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of necitumumab in non-small cell lung cancer, squamous cell carcinoma (NSCLC), sponsored by Montefiore Medical Center. Primary endpoint: Proportion of Patients Able to Proceed to Surgery up to 63 days. Started May 2018; status: terminated.
02
Drugs
necitumumab
03
Conditions
non-small cell lung cancer, squamous cell carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT03574818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574818.